NOTIFICATION OF REMOVAL FROM LISTING AND/OR REGISTRATION UNDER SECTION 12(b) OF THE SECURITIES EXCHANGE ACT OF 1934.
UNITED STATES
OMB APPROVAL
OMB Number: 3235-0080
Expires: December 31, 2014
Estimated average burden
hours per response: 1.7
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 25
NOTIFICATION OF REMOVAL FROM LISTING AND/OR REGISTRATION
UNDER SECTION 12(b) OF THE SECURITIES EXCHANGE ACT OF 1934.
Commission File Number 001-37797
Issuer: INNOVATE BIOPHARMACEUTICALS, INC.
Exchange: The Nasdaq Stock Market LLC
(Exact name of Issuer as specified in its charter, and name of Exchange where security is listed and/or registered)
Address: 2655 Park Center Drive, Unit C
Simi Valley CALIFORNIA 93065
Telephone number: 8,059,554,190
(Address, including zip code, and telephone number, including area code, of Issuer's principal executive offices)
Warrant
(Description of class of securities)
Please place an X in the box to designate the rule provision relied upon to strike the class of securities from listing and registration:
17 CFR 240.12d2-2(a)(1)
17 CFR 240.12d2-2(a)(2)
17 CFR 240.12d2-2(a)(3)
17 CFR 240.12d2-2(a)(4)
Pursuant to 17 CFR 240.12d2-2(b), the Exchange has complied with its rules to strike the class of securities from listing and/or withdraw registration on the Exchange. 1
Pursuant to 17 CFR 240.12d2-2(c), the Issuer has complied with its rules of the Exchange and the requirements of 17 CFR 240.12d-2(c) governing the voluntary withdrawal of the class of securities from listing and registration on the Exchange.
Pursuant to the requirements fo the Securities Exchange Act of 1934, The Nasdaq Stock Market LLC certifies that it has reasonable grounds to believe that it meets all of the requirements for filing the Form 25 and has caused this notification to be signed on its behalf by the undersigned duly authorized person.
2018-04-19 By Amy Horton Hearings Advisor
Date Name Title
1 Form 25 and attached Notice will be considered compliance with the provisions of 17 CFR 240.19d-1 as applicable. See General Instructions.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
Delisting Determination,The Nasdaq Stock Market, LLC,
April 19, 2018, Innovate Biopharmaceuticals, Inc. The Nasdaq 
Stock Market, Inc. (the Exchange) has determined to remove 
from listing the warrant of Innovate Biopharmaceuticals, Inc.
(the Company), effective at the opening of the trading 
session on April 30, 2018. Based on review of information 
provided by the Company, Nasdaq Staff determined that the 
Company no longer qualified for listing on the Exchange 
pursuant to Listing Rule 5550(b)(1). The Company was notified 
of the Staffs determination on October 19, 2017.  
The Company appealed the determination 
to a Hearing Panel. Upon review of the information provided 
by the Company, the Panel issued a decision dated 
December 11, 2017, granting the Company continued listing 
pursuant to an exception that included several milestones 
that the Company was required to meet, towards the toal 
of regaining compliance with Listing Rules 5550(b)(1), 5550(a)(2), 
5555(a)(2) and 5620(a). The Company met the exception milestones
for its common stock, however, the Company was 
unable to meet the exception milestones for the warrant. 
On February 27, 2018, the Panel issued a final compliance 
determination for the common stock and notified the
 
Company that trading in the Companys 
warrant would be suspended on March 5, 2018. 
The Company did not request a review of the Panels decision 
by the Nasdaq Listing and Hearing Review Council. The 
Listing Council did not call the matter for review. 
The Panels Determination to delist the Companys warrant 
became final on March 5, 2018.